Moderna’s mNEXSPIKE generates strong immune response against LP.8.1 variant in humans
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
The new site enables end-to-end production of viral vector gene therapies
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
Subscribe To Our Newsletter & Stay Updated